ReviewFrontiers in endocrinology2026
Macrohormones in endocrinology: prevalence, clinical impact, and diagnostic approaches.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrohormones also called macromolecules or macrocomplexes are described as an antigen-antibody complex, consisting of monomeric hormones bound to immunoglobulins. These molecules exhibit minimal or no biological activity. However, their presence may falsely indicate elevation of active hormones levels which can lead to significant diagnostic challenges. Currently, polyethylene glycol precipitation (PEG) is one of the most recognized methods for identifying macrohormones and it has been widely used in diagnosing macroprolactinemia as awareness of its clinical implications is well recognized. Macrohormone assessment is particularly recommended when clinical symptoms are incompatible with laboratory findings, as it may help avoid unnecessary diagnostic procedures and treatments. Recently, there has been an increasing number of reports highlighting diagnostic challenges associated with other macrohormones, including macro-TSH, macro-FSH, macro-LH, macro-PTH, macro-GH, macro-ACTH, macro-insulin, and macro-calcitonin. The presence of these molecules can lead to overdiagnosis. This review aims to summarize the latest findings and highlight the importance of considering the presence of macrohormones in patients with discrepancies between clinical presentation and hormonal laboratory tests.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.